Immunotherapy in genitourinary tumors

This month Prof. Sandy Srinivas and Prof. David Pfister provide an interesting overview of Immunotherapy in genitourinary tumors.

Immunotherapy in genitourinary tumors

Immunotherapy in genitourinary tumors

GU medical oncologists Prof. Sandy Srinivas and Prof. David Pfister give us an insight into the use of immunotherapy in the treatment of genitourinary tumours. Focus is on the toxicity of check-point inhibitors, and handling for best patient care. In this slide and video set they cover which immunotherapies are indicated for use in urothelial carcinoma, prostate cancer, and renal cell cancer.

Considering outcomes and side effects

Discussed are side effects of immunotherapy in renal cell cancer including immune associated side effects, acute phase reactions, and haematotoxicity. Also covered is the FDA approval status of check-point inhibitors including the monoclonal PD-1 and PD-L1 antibodies: durvalumab, pembrolizumab, nivolumab, and atezolizumab. There is an examination of data on overall survival and side effects in a study of nivolumab verses everolimus treatment of renal cell carcinoma (RCC). Additionally, data are presented from two separate studies detailing side effects of nivolumab and atezolizumab in the treatment of urothelial carcinoma. Finally, a discussion on how to spot and manage side effects. Gain clinical insight into immunotherapy use in genitourinary cancer by watching the video and downloading the slides.